Business Context and Reporting Period
This Form 8-K is a current report filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on June 22, 2018, regarding events occurring on June 20, 2018. The filing details the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (April 21, 2018), there were 27,146,099 outstanding shares of common stock. Stockholders approved three proposals:
- Proposal 1 (Director Election): Elected Cheryl Cohen, Caley Castelein, and Stephen Hoffman as Class I directors for a three-year term.
- Proposal 2 (Auditor Ratification): Ratified the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Proposal 3 (ESPP Approval): Approved the Amended and Restated 2017 Employee Stock Purchase Plan.
Voting Breakdown
| Proposal | For | Against/Withhold | Abstain/Non-Votes |
|---|---|---|---|
| Proposal 1 (Directors) | ~18.45M (per nominee) | ~10k-11k (per nominee) | 995,204 (Broker Non-Votes) |
| Proposal 2 (Auditor) | 19,429,410 | 4,086 | 20,000 |
| Proposal 3 (ESPP) | 18,348,242 | 30,050 | 80,000 |
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. It is a procedural report of shareholder voting.
Investor Verification Checklist
- Verify the registrant name is Aerpio Pharmaceuticals, Inc., not Whitehawk Therapeutics, Inc.
- Confirm the election of the three Class I directors and their three-year terms.
- Review the Definitive Proxy Statement filed on May 15, 2018, for detailed descriptions of the approved proposals.
- Note the high number of broker non-votes (995,204) on the director election, which did not affect the outcome but indicates significant passive holdings.